Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.

Adeline HeraudeauAurélien DellucMickaël Le HenaffKarine LacutChristophe LeroyerBenoit DesruesFrancis CouturaudCécile Tromeur

Published in: PloS one (2018)

The pro-thrombotic Factor V Leiden mutation was found to be an independent additional risk factor for venous thromboembolism in cancer patients and might therefore be considered in the individual thrombotic risk assessment.

Keyphrases

venous thromboembolism
risk assessment
direct oral anticoagulants
human health
anti inflammatory